A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma [PDF]
Scientific ReportsMany cancers evade immunosurveillance by downregulating surface major histocompatibility class (MHC)-I. Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes MHC-I degradation and is elevated in glioma.
Kirit Singh +27 more
doaj +2 more sources
Evolocumab Added to Statin Is Associated With Intracranial Atherosclerotic Plaque Regression Compared With Statin Alone [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground We aimed to investigate the effects of evolocumab, a proprotein convertase subtilisin/kexin type‐9 inhibitor for intensive lipid‐lowering, on intracranial atherosclerotic stenosis.
Xinzhi Hu +12 more
doaj +2 more sources
The impact of the national reimbursement drug list negotiation policy on the accessibility and utilization of evolocumab and alirocumab in different levels of hospitals: an interrupted time series analysis [PDF]
Frontiers in PharmacologyObjectiveIn December 2021, evolocumab and alirocumab were included in the National Reimbursement Drug List Negotiation (NRDLN), with implementation commencing in January 2022.
Wan Tang +10 more
doaj +2 more sources
Indirect comparison of the efficacy and safety of alirocumab and evolocumab on major cardiovascular events: a systematic review and network meta-analysis [PDF]
Frontiers in PharmacologyBackgroundAlirocumab and evolocumab are proprotein convertase subtilisin/kexin type 9 inhibitors that significantly reduce the relative risk of cardiovascular events.
Leyu Xu +11 more
doaj +2 more sources
Real-World Safety and Effectiveness of Evolocumab in Korean Patients with Atherosclerotic Cardiovascular Disease or Familial Hypercholesterolemia: A Post-Marketing Surveillance Study [PDF]
Cardiology and TherapyIntroduction The efficacy and safety of evolocumab have been established in clinical trials. This post-marketing surveillance (PMS) study investigated the real-world safety and effectiveness of evolocumab in patients with atherosclerotic cardiovascular ...
Donggyu Moon +8 more
doaj +2 more sources
New approaches in detection and treatment of familial hypercholesterolemia [PDF]
, 2015 Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder that clinically leads to increased low density lipoprotein-cholesterol (LDL-C) levels. As a consequence, FH patients are at high risk for cardiovascular disease (CVD). Mutations
Hartgers, ML, Hovingh, GK, Ray, KK
core +12 more sources
PLoS ONE, 2023 ObjectivesDyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study aimed to describe the characteristics of patients receiving evolocumab in clinical practice ...
Khalid Al Faraidy +10 more
doaj +1 more source
Cardiology and Therapy, 2023 Introduction Evolocumab, a fully human proprotein convertase/subtilisin kexin type 9 inhibitor antibody, significantly lowers low-density lipoprotein cholesterol (LDL-C) in patients with type 2 diabetes mellitus and hyperlipidemia and mixed dyslipidemia.
Hong Tan +12 more
doaj +1 more source
Nefrología (English Edition), 2022 Background and objective: To describe the clinical characteristics, the reasons for initiating therapy and the effects of treatment in the initial phase of evolocumab availability in the Nephrology Units of Spain.
Marian Goicoechea +15 more
doaj +1 more source